146 related articles for article (PubMed ID: 22354912)
21. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
[TBL] [Abstract][Full Text] [Related]
23. Anti-VEGF antibody enhances the antitumor effect of CD40.
Selvaraj S; Raundhal M; Patidar A; Saha B
Int J Cancer; 2014 Oct; 135(8):1983-8. PubMed ID: 24604357
[TBL] [Abstract][Full Text] [Related]
24. Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice.
Jackaman C; Radley-Crabb HG; Soffe Z; Shavlakadze T; Grounds MD; Nelson DJ
Aging Cell; 2013 Jun; 12(3):345-57. PubMed ID: 23442123
[TBL] [Abstract][Full Text] [Related]
25. CD40-activated B cells contribute to mesothelioma tumor regression.
Jackaman C; Cornwall S; Graham PT; Nelson DJ
Immunol Cell Biol; 2011 Feb; 89(2):255-67. PubMed ID: 20628372
[TBL] [Abstract][Full Text] [Related]
26. Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution.
Jackaman C; Nelson DJ
Cancer Gene Ther; 2010 Jun; 17(6):429-40. PubMed ID: 20150930
[TBL] [Abstract][Full Text] [Related]
27. Triggering of murine NK cells by CD40 and CD86 (B7-2).
Martín-Fontecha A; Assarsson E; Carbone E; Kärre K; Ljunggren HG
J Immunol; 1999 May; 162(10):5910-6. PubMed ID: 10229827
[TBL] [Abstract][Full Text] [Related]
28. Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases.
Teng MW; von Scheidt B; Duret H; Towne JE; Smyth MJ
Cancer Res; 2011 Mar; 71(6):2077-86. PubMed ID: 21282337
[TBL] [Abstract][Full Text] [Related]
29. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model.
Alici E; Konstantinidis KV; Sutlu T; Aints A; Gahrton G; Ljunggren HG; Dilber MS
Exp Hematol; 2007 Dec; 35(12):1839-46. PubMed ID: 18036444
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW
BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732
[TBL] [Abstract][Full Text] [Related]
32. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
33. Protective effect of NK1.1(+) T cells as well as NK cells against intraperitoneal tumors in mice.
Kawamura T; Seki S; Takeda K; Narita J; Ebe Y; Naito M; Hiraide H; Abo T
Cell Immunol; 1999 May; 193(2):219-25. PubMed ID: 10222065
[TBL] [Abstract][Full Text] [Related]
34. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
35. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Lum HD; Buhtoiarov IN; Schmidt BE; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Leukoc Biol; 2006 Jun; 79(6):1181-92. PubMed ID: 16565324
[TBL] [Abstract][Full Text] [Related]
36. Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases.
von Scheidt B; Leung PS; Yong MC; Zhang Y; Towne JE; Smyth MJ; Teng MW
Cancer Res; 2014 May; 74(9):2412-21. PubMed ID: 24556719
[TBL] [Abstract][Full Text] [Related]
37. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
[TBL] [Abstract][Full Text] [Related]
38. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
Zhang M; Ju W; Yao Z; Yu P; Wei BR; Simpson RM; Waitz R; Fassò M; Allison JP; Waldmann TA
J Immunol; 2012 Jun; 188(12):6156-64. PubMed ID: 22593619
[TBL] [Abstract][Full Text] [Related]
39. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
Mangsbo SM; Broos S; Fletcher E; Veitonmäki N; Furebring C; Dahlén E; Norlén P; Lindstedt M; Tötterman TH; Ellmark P
Clin Cancer Res; 2015 Mar; 21(5):1115-26. PubMed ID: 25316820
[TBL] [Abstract][Full Text] [Related]
40. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]